Publications
Detailed Information
Corrigendum to Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024](S0923753421015532)(10.1016/j.annonc.2021.05.353)
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Slamon, D.J. | - |
| dc.contributor.author | Neven, P. | - |
| dc.contributor.author | Chia, S. | - |
| dc.contributor.author | Jerusalem, G. | - |
| dc.contributor.author | De, Laurentiis M. | - |
| dc.contributor.author | Im, S. | - |
| dc.contributor.author | Petrakova, K. | - |
| dc.contributor.author | Valeria, Bianchi G. | - |
| dc.contributor.author | Martin, M. | - |
| dc.contributor.author | Nusch, A. | - |
| dc.contributor.author | Sonke, G.S. | - |
| dc.contributor.author | De, la Cruz-Merino L. | - |
| dc.contributor.author | Beck, J.T. | - |
| dc.contributor.author | Ji, Y. | - |
| dc.contributor.author | Wang, C. | - |
| dc.contributor.author | Deore, U. | - |
| dc.contributor.author | Chakravartty, A. | - |
| dc.contributor.author | Zarate, J.P. | - |
| dc.contributor.author | Taran, T. | - |
| dc.contributor.author | Fasching, P.A. | - |
| dc.date.accessioned | 2023-03-20T08:50:32Z | - |
| dc.date.available | 2023-03-20T08:50:32Z | - |
| dc.date.created | 2022-04-15 | - |
| dc.date.created | 2022-04-15 | - |
| dc.date.issued | 2021-10 | - |
| dc.identifier.citation | Annals of Oncology, Vol.32 No.10, pp.1307-1307 | - |
| dc.identifier.issn | 0923-7534 | - |
| dc.identifier.uri | https://hdl.handle.net/10371/189537 | - |
| dc.description.abstract | © 2021 The Author(s)The authors regret that at the time the article was published, Supplementary Table S2 contained errors. This has now been corrected. The authors would like to apologise for any inconvenience caused. | - |
| dc.language | 영어 | - |
| dc.publisher | Oxford University Press | - |
| dc.title | Corrigendum to Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024](S0923753421015532)(10.1016/j.annonc.2021.05.353) | - |
| dc.type | Article | - |
| dc.identifier.doi | 10.1016/j.annonc.2021.07.011 | - |
| dc.citation.journaltitle | Annals of Oncology | - |
| dc.identifier.wosid | 000709095000017 | - |
| dc.identifier.scopusid | 2-s2.0-85112792663 | - |
| dc.citation.endpage | 1307 | - |
| dc.citation.number | 10 | - |
| dc.citation.startpage | 1307 | - |
| dc.citation.volume | 32 | - |
| dc.description.isOpenAccess | Y | - |
| dc.contributor.affiliatedAuthor | Im, S. | - |
| dc.type.docType | Erratum | - |
| dc.description.journalClass | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.